Once the capacity of 4PD to bind and transfect myeloid cells in vivo with multiple shRNAs was determined, we evaluated the effect of chronic CCR1, CCR2, CCR5, and CCR7 silencing on tumor progression. The gene discussed is CCR5; the disease is neoplasm.